Ionis Pharmaceuticals competitors, on the record

Who Ionis Pharmaceuticals names

In its own words

1. Alnylam

   Word for word“Onpattro (Patisiran) Alnylam An RNAi medicine formulated with lipid nanoparticles to inhibit TTR mRNA Approved in U.S., EU, Japan and select other markets for ATTRv-PN Intravenous Infusion” 10-K for 2025

2. Arrowhead Pharmaceuticals

   Word for word“Redemplo (Plozasiran) Arrowhead Pharmaceuticals Targets APOCIII by utilizing Targeted RNAi Molecule Platform Approved in U.S. for FCS, under review in the EU for FCS, Phase 3 sHTG Subcutaneous Injection” 10-K for 2025

3. Novartis

   Word for word“Zolgensma (Onasemnogene abeparvovec) Novartis Gene therapy targeting the genetic root cause of SMA by replacing the missing or nonworking SMN1 gene Approved for pediatric SMA patients less than 2 years of age Intravenous Infusion” 10-K for 2025

4. Pfizer

   Word for word“Vyndaqel/Vyndamax (Tafamidis and tafamidis meglumine) Pfizer A small molecule medicine to stabilize TTR protein” 10-K for 2025

5. Roche

   Word for word“Evrysdi (Risdiplam) Roche A small molecule medicine that modulates splicing of the SMN2 gene Approved for SMA in pediatric and adult patients Oral” 10-K for 2025

6. Takeda

   Word for word“Takhzyro (lanadelumab-flyo) Takeda A monoclonal antibody that inhibits plasma kallikrein activity Approved for HAE patients two years and older Subcutaneous Injection” 10-K for 2025

Read from Ionis Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.